US 11,865,276 B2
Vascular occlusion and drug delivery devices, systems, and methods
Edward H. Cully, Newark, DE (US); Jeffrey B. Duncan, Flagstaff, AZ (US); Douglas S. Paget, Flagstaff, AZ (US); Rachel Radspinner, Flagstaff, AZ (US); Edward E. Shaw, Flagstaff, AZ (US); and Michael J. Vonesh, Flagstaff, AZ (US)
Assigned to W. L. Gore & Associates, Inc., Newark, DE (US)
Filed by W. L. Gore & Associates, Inc., Newark, DE (US)
Filed on Jan. 28, 2021, as Appl. No. 17/160,838.
Application 17/160,838 is a continuation of application No. 15/882,163, filed on Jan. 29, 2018, granted, now 10,926,064.
Application 15/882,163 is a continuation of application No. 13/914,473, filed on Jun. 10, 2013, granted, now 9,878,132, issued on Jan. 30, 2018.
Claims priority of provisional application 61/660,615, filed on Jun. 15, 2012.
Prior Publication US 2021/0170146 A1, Jun. 10, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 25/10 (2013.01); A61B 17/12 (2006.01); A61M 5/00 (2006.01); A61B 17/00 (2006.01)
CPC A61M 25/10 (2013.01) [A61B 17/12022 (2013.01); A61B 17/12109 (2013.01); A61B 17/12131 (2013.01); A61M 5/00 (2013.01); A61B 17/1214 (2013.01); A61B 17/12145 (2013.01); A61B 17/12159 (2013.01); A61B 17/12181 (2013.01); A61B 2017/00004 (2013.01); A61B 2017/00778 (2013.01); A61B 2017/00884 (2013.01); A61B 2017/00893 (2013.01); A61M 2025/1004 (2013.01); A61M 2025/105 (2013.01); A61M 2025/1065 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A vascular delivery device comprising:
an inner expandable member;
a drug infusible layer having a sleeve that circumscribes, is mounted around, or is situated about the inner expandable member defining at least a portion of interstitial space, the interstitial space at least partially containing a therapeutic agent, and the drug infusible layer being associated with the inner expandable member;
an outer barrier, wherein the outer barrier circumscribes or is mounted around the drug infusible layer; and
a tethering device comprising a guidewire, filament, or thread coupled to a distal end of the inner expandable member, the tethering device configured to:
(a) retract the inner expandable member and the drug infusible layer into a retracted position by pulling on the guidewire, filament, or thread to prevent the therapeutic agent from being transferred through the outer barrier; and
(b) extend the inner expandable member and the drug infusible layer into an extended position via pressurization to allow the therapeutic agent to transfer from the interstitial space of the drug infusible layer through the outer barrier in response to being compressed against an exterior vessel wall.